Skip to main content
Equibles

RDY · Dr Reddys Laboratories Ltd · Metrics

Track RDY — free

Use RDY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RDY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.15 +0.40 (+2.91%) At close · Oct 28 Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$11.73B
Shares
833.07M
Volume · Oct 28 4.47M Avg daily vol (3M) 2.92M

RDY metrics

62 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$14.15
Market cap
$11.73B

Price action

20 metrics
Price change (1W)
+3.7%
Price change (30D)
+9.9%
Price change (3M)
+17.2%
Price change (6M)
-2.0%
Price change (YTD)
-2.1%
Price change (1Y)
-5.0%
Trailing year
Price change (5Y)
—
52-week high
$15.38
52-week low
$11.38
Change from 52-week high
-10.6%
Change from 52-week low
+20.8%
Annualized volatility
27.7%
Annualized volatility (3M)
21.9%
Beta
0.3
RSI (14D)
73.9
Price vs SMA 50
+10.7%
Price vs SMA 200
+4.1%
Avg volume (3M)
2.92M
Relative volume
1.6
Average dollar volume
$36.14M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
833.07M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.9
reciprocal yield 35.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
0.6%
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
$0.08
Dividend growth YoY
-8.8%
Dividend growth streak
0
Last ex-dividend
2026-07-24

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-09-30

Profitability

9 metrics
Gross margin
52.8%
Operating margin
15.0%
Trailing 12 months
Net margin
12.8%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$451.76

Growth

11 metrics
Revenue growth YoY
+3.2%
Year over year
Net income growth YoY
-24.2%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-24.1%
Shares change YoY
+0.0%
Year over year · more shares
Revenue CAGR (3Y)
+11.0%
Revenue CAGR (5Y)
+12.1%
EPS CAGR (3Y)
-1.7%
EPS CAGR (5Y)
+19.9%
FCF CAGR (3Y)
-11.1%
FCF CAGR (5Y)
+5.2%

Quality

14 metrics
Return on equity
11.4%
Return on assets
7.4%
Debt / equity
—
Current ratio
1.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$163.79M
Total assets
$6.17B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
240
13F filer change QoQ
-11
Institutional ownership
15.1%
Conviction holders (share of 13F filers)
0.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+1.1%
Holder tenure
16.9
Price vs estimated holder cost
+5.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.2%

Short interest

3 metrics
Short interest
3.1%
Latest settlement · 8.5 days to cover
Days to cover
8.5d
Short-squeeze score
81 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1135951 CUSIP 256135203 13F (30d) 56 filings 51 filers Visit website Investor relations